PE122699A1 - Antagonistas de receptores de vitronectina - Google Patents
Antagonistas de receptores de vitronectinaInfo
- Publication number
- PE122699A1 PE122699A1 PE1998000881A PE00088198A PE122699A1 PE 122699 A1 PE122699 A1 PE 122699A1 PE 1998000881 A PE1998000881 A PE 1998000881A PE 00088198 A PE00088198 A PE 00088198A PE 122699 A1 PE122699 A1 PE 122699A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- refers
- compound
- receptor antagonists
- halo
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 102100022337 Integrin alpha-V Human genes 0.000 title 1
- 108010048673 Vitronectin Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5934297P | 1997-09-19 | 1997-09-19 | |
| US6343897P | 1997-10-29 | 1997-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE122699A1 true PE122699A1 (es) | 2000-02-12 |
Family
ID=26738652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000881A PE122699A1 (es) | 1997-09-19 | 1998-09-16 | Antagonistas de receptores de vitronectina |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1025090A4 (sk) |
| JP (1) | JP2001517658A (sk) |
| KR (1) | KR20010024141A (sk) |
| CN (1) | CN1278250A (sk) |
| AP (1) | AP2000001766A0 (sk) |
| AR (1) | AR015446A1 (sk) |
| AU (1) | AU738433B2 (sk) |
| BG (1) | BG104314A (sk) |
| BR (1) | BR9812340A (sk) |
| CA (1) | CA2303487A1 (sk) |
| CO (1) | CO5011087A1 (sk) |
| DZ (1) | DZ2609A1 (sk) |
| EA (1) | EA200000336A1 (sk) |
| HU (1) | HUP0003641A3 (sk) |
| ID (1) | ID24162A (sk) |
| IL (1) | IL135028A0 (sk) |
| MA (1) | MA26547A1 (sk) |
| NO (1) | NO20001407D0 (sk) |
| NZ (1) | NZ503389A (sk) |
| OA (1) | OA11341A (sk) |
| PE (1) | PE122699A1 (sk) |
| PL (1) | PL339381A1 (sk) |
| SK (1) | SK4082000A3 (sk) |
| TR (1) | TR200000721T2 (sk) |
| TW (1) | TW513303B (sk) |
| WO (1) | WO1999015508A1 (sk) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| WO2000046215A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
| DE19936780A1 (de) | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6720315B2 (en) | 2000-06-15 | 2004-04-13 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives |
| JP2004513953A (ja) * | 2000-10-24 | 2004-05-13 | メルク エンド カムパニー インコーポレーテッド | ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト |
| AU2002316855B2 (en) | 2001-04-24 | 2008-03-13 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and TNFalpha |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| KR20080089489A (ko) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 |
| US20100069302A1 (en) | 2007-07-18 | 2010-03-18 | Stefan Krueger | Specific therapy and medicament using integrin ligands for treating cancer |
| SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| JP6649902B2 (ja) | 2014-05-30 | 2020-02-19 | ファイザー・インク | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH450398A (de) * | 1964-02-18 | 1968-01-31 | Hoffmann La Roche | Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen |
| US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
| US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
| SI0910563T1 (en) * | 1995-06-29 | 2003-10-31 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
| WO1998015278A1 (en) * | 1996-10-07 | 1998-04-16 | Smithkline Beecham Corporation | Method for stimulating bone formation |
| CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
-
1998
- 1998-09-16 AR ARP980104604A patent/AR015446A1/es not_active Application Discontinuation
- 1998-09-16 PE PE1998000881A patent/PE122699A1/es not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/xx active
- 1998-09-18 ID IDW20000468A patent/ID24162A/id unknown
- 1998-09-18 EP EP98947116A patent/EP1025090A4/en not_active Withdrawn
- 1998-09-18 CO CO98053986A patent/CO5011087A1/es unknown
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/hu unknown
- 1998-09-18 EA EA200000336A patent/EA200000336A1/ru unknown
- 1998-09-18 IL IL13502898A patent/IL135028A0/xx unknown
- 1998-09-18 MA MA25266A patent/MA26547A1/fr unknown
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/en not_active Ceased
- 1998-09-18 CA CA002303487A patent/CA2303487A1/en not_active Abandoned
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/ja not_active Withdrawn
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/pt not_active Application Discontinuation
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/ko not_active Ceased
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/xx unknown
- 1998-09-18 CN CN98810811A patent/CN1278250A/zh active Pending
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/sk unknown
- 1998-09-18 PL PL98339381A patent/PL339381A1/xx unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-23 TW TW087115535A patent/TW513303B/zh not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/no not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0003641A3 (en) | 2002-10-28 |
| MA26547A1 (fr) | 2004-12-20 |
| BR9812340A (pt) | 2001-12-18 |
| NO20001407L (no) | 2000-03-17 |
| EA200000336A1 (ru) | 2000-10-30 |
| AR015446A1 (es) | 2001-05-02 |
| KR20010024141A (ko) | 2001-03-26 |
| NZ503389A (en) | 2002-03-28 |
| AU738433B2 (en) | 2001-09-20 |
| BG104314A (en) | 2001-01-31 |
| HUP0003641A2 (en) | 2001-03-28 |
| ID24162A (id) | 2000-07-13 |
| TR200000721T2 (tr) | 2000-11-21 |
| WO1999015508A1 (en) | 1999-04-01 |
| SK4082000A3 (en) | 2000-09-12 |
| AP2000001766A0 (en) | 1998-09-18 |
| EP1025090A1 (en) | 2000-08-09 |
| TW513303B (en) | 2002-12-11 |
| EP1025090A4 (en) | 2000-11-08 |
| CO5011087A1 (es) | 2001-02-28 |
| OA11341A (en) | 2003-12-10 |
| CA2303487A1 (en) | 1999-04-01 |
| CN1278250A (zh) | 2000-12-27 |
| JP2001517658A (ja) | 2001-10-09 |
| IL135028A0 (en) | 2001-05-20 |
| NO20001407D0 (no) | 2000-03-17 |
| AU9397298A (en) | 1999-04-12 |
| DZ2609A1 (fr) | 2003-03-01 |
| PL339381A1 (en) | 2000-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE122699A1 (es) | Antagonistas de receptores de vitronectina | |
| NZ336560A (en) | 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists | |
| DOP2001000271A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes antiinflamatorios y analgésicos. | |
| EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
| BR9916790A (pt) | Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente | |
| BR9408325A (pt) | Composto composição farmacêutica e processo para a manufatura de um composto | |
| IL150986A0 (en) | 1,2,3,4,- tetrahydroisoquinoline derivatives | |
| EP0946165A4 (en) | INTEGRIN ANTAGONIST | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| ES2187675T3 (es) | (metilsulfonil)fenil-2-(5h)-furanonas como inhibidores de cox-2. | |
| EA200000682A1 (ru) | Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов | |
| EP0896533A4 (en) | PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS | |
| PT894084E (pt) | Derivados de acido cinamico e sua utilizacao como antagonistas de integrina | |
| ES2063146T3 (es) | Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico. | |
| EP1425010A4 (en) | SUBSTITUTED INDOLE AND ITS USE AS INTEGRIN ANTAGONISTS | |
| BR9810729B1 (pt) | composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. | |
| ATE327748T1 (de) | Alkandiol derivate zur behandlung von knochenkrankheiten | |
| PE20001563A1 (es) | Antagonistas del receptor de vitronectina | |
| DK0808303T3 (da) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister | |
| WO2002022616A3 (en) | Alpha v integrin receptor antagonists | |
| AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
| BR0316724A (pt) | Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas | |
| PE20010582A1 (es) | Antagonistas de los receptores de vitronectina | |
| AR024411A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas. | |
| FR2804958B1 (fr) | Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |